Visit https://www.peervoice.com/BJJ860 to view the entire programme with slides. After completing “Francesco Cappelli, MD, PhD - Meaningful Data From Madrid: Expanding Our Understanding of Phase 3s and OLEs in ATTR-CM”, participants will be able to: Identify the impact of disease-modifying therapies on accepted markers of transthyretin amyloid cardiomyopathy (ATTR-CM) disease severity, including NT-proBNP, 6MWD, and NAC stage in phase 3 trial populations; and Evaluate recently presented outcomes from post-hoc analyses and open-label extensions of phase 3 trials in ATTR-CM in the context of previously published and presented outcomes across the landscape of disease-modifying therapies.

Visit https://www.peervoice.com/VBS860 to view the entire programme with slides. After completing “Nicoletta Policek, PhD - When You Are Not an HIV Specialist But You Are Addressing Broader Healthcare Needs of Individuals With HIV: What Do You Need to Know?”, participants will be able to: Identify strategies to improve communication between people living with HIV (PWLH) and healthcare providers (HCPs), reduce HCP stigma, and build positive perceptions of health management by non-HIV specialist HCPs; and Propose key practical preventative steps for HIV-associated comorbidities.

Visit https://www.peervoice.com/MWF860 to view the entire programme with slides. After completing “Geneviève Matte, MDCM, FRCPC - Improving Early Diagnosis of hATTR Amyloidosis: A Critical Step Towards Better Outcomes”, participants will be able to: Describe current challenges in the diagnosis of hereditary transthyretin (hATTR) amyloidosis; Outline key manifestations that should prompt screening for hATTR amyloidosis; and Discuss expert recommendations to facilitate diagnosis, including key assessments to help identify patients with hATTR amyloidosis earlier.

Visit https://www.peervoice.com/KHV860 to view the entire programme with slides. After completing “Isabel Conceição, MD - Prioritizing Patient-Centered Care for ATTR: Expert Perspectives on the Evolution of Data and Decision-Making”, participants will be able to: Identify best practices to optimize the recognition and diagnosis of patients with transthyretin amyloidosis (ATTR), including those with ATTRv-PN and those with mixed phenotype ATTR; Evaluate current and emerging treatment options for hereditary ATTR with polyneuropathy (ATTRv-PN), including key differences between therapies with regards to clinical trial design, patient populations studied, available outcomes, and administration considerations; and Apply a comprehensive, patient-centered approach to management of patients with ATTR, including those with ATTRv-PN and those with mixed phenotype ATTR.

Visit https://www.peervoice.com/DRF860 to view the entire programme with slides. After completing “Michael Thorpy, MD - When Sleep Is Exhausting: Improving Diagnosis and Outcomes in Patients With Idiopathic Hypersomnia”, participants will be able to: Recognize health risks associated with idiopathic hypersomnia; Differentiate idiopathic hypersomnia from other conditions that cause excessive daytime sleepiness (EDS); Explain how to establish a confirmatory diagnosis of idiopathic hypersomnia; and Propose effective, individualized, evidence-based management strategies for patients with idiopathic hypersomnia.

Visit https://www.peervoice.com/RHA860 to view the entire programme with slides. After completing “Phyllis C. Zee, MD, PhD - Sleep, Heart, Brain: What Promotes and How to Reduce Cardiovascular Risk in Patients With Narcolepsy”, participants will be able to: Describe the pathophysiology of narcolepsy in the context of cardiovascular (CV) effects; Differentiate between narcolepsy medications regarding their impact on CV risk factors; Identify medications used for common comorbidities associated with narcolepsy that have the potential to increase CV risk; and Propose strategies to manage CV risk in patients with narcolepsy.

Visit https://www.peervoice.com/UET860 to view the entire programme with slides. After completing “Perry Elliott, MD, FRCP - What’s New and What’s Next? Expanding Our Understanding of HCM in 2023”, participants will be able to: Discuss emerging clinical data related to the management of hypertrophic cardiomyopathy (HCM); Describe the latest updates on guideline recommendations for provision of evidence-based care for patients with HCM; and Use emerging clinical data and latest updates on guideline recommendations to manage patients with HCM.

Visit https://www.peervoice.com/JHP860 to view the entire programme with slides. After completing “Claus Vogelmeier, MD - Approaching Airway Inflammation From Another Angle: The Rationale for Targeting Type 2 Pathways in COPD”, participants will be able to: Identify current unmet needs in the achievement of goals of care in patients with chronic obstructive pulmonary disease (COPD); Describe the role of type 2 inflammation in the pathophysiology of COPD; and Evaluate emerging efficacy and safety data for the use of biologic therapies in the treatment of COPD.

Visit https://www.peervoice.com/HPG860 to view the entire programme with slides. After completing “Perry Elliott, MD, FRCP - Continuing Our Conversation in HCM: Compelling Questions and Evolving Considerations”, participants will be able to:

Visit https://www.peervoice.com/THW860 to view the entire programme with slides. After completing “Laura Obici, MD - Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (ATTR): Shared Perspectives From Patients and Providers”, participants will be able to: Identify unmet needs in the identification and diagnosis of patients with transthyretin amyloidosis (ATTR); and Apply recommended approaches to promote accurate and timely diagnosis and intervention in ATTR.

Visit https://www.peervoice.com/PHB860 to view the entire programme with slides. After completing “Peter J. Lin, MD, CCFP - Severe Uncontrolled Versus Difficult-to-Treat Asthma: Strategies for Detection, Differentiation, and Referral”, participants will be able to: Differentiate difficult-to-treat from severe uncontrolled asthma; Identify patients who are likely to benefit from an early referral to a specialist; and Discuss potential barriers in the severe asthma referral process and strategies to overcome them.

Visit https://www.peervoice.com/CFX860 to view the entire programme with slides. After completing “Michael Thorpy, MD - Dual Duty: Protecting Cardiovascular Health in Patients With Narcolepsy ”, participants will be able to: Explain the relationship between the pathophysiology of narcolepsy and cardiovascular (CV) risk; Identify contributors to CV risk in patients with narcolepsy; and Design practical approaches to reduce CV risk in patients receiving medications for narcolepsy.

Visit https://www.peervoice.com/UTG860 to view the entire programme with slides. After completing “Peter J. Lin, MD, CCFP - Severe Uncontrolled Versus Difficult-to-Treat Asthma: Strategies for Detection, Differentiation, and Referral”, participants will be able to: Differentiate difficult-to-treat from severe uncontrolled asthma; Identify patients who are likely to benefit from an early referral to a specialist; and Discuss potential barriers in the severe asthma referral process and strategies to overcome them.

Visit https://www.peervoice.com/GXR860 to view the entire programme with slides. After completing “Javed Butler, MD, MPH, MBA - Changing the Patient Journey Across the Spectrum of Heart Failure”, participants will be able to: Recognise the different pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF) versus HF with reduced ejection fraction (HFrEF); Summarise how SGLT2 inhibitors are changing the treatment paradigm for HFpEF and HFrEF; and Apply updated strategies to management of patients with HFpEF and HFrEF, with the goal of improving outcomes.

Visit https://www.peervoice.com/MWY860 to view the entire programme with slides. After completing “Taking the Latest Evidence to Heart: Optimizing Therapy in Patients With HFrEF After a Worsening Event”, participants will be able to: Describe the latest clinical evidence for novel pharmacological therapies used in patients with heart failure and reduced ejection fraction (HFrEF) after a worsening event; Identify patient profiles that would benefit from this therapy; and Outline practical considerations to optimize therapy and improve outcomes in patients with HF after a worsening event.

Visit https://www.peervoice.com/UMY860 to view the entire programme with slides. After completing “If I'd Known Then What I Know Now: Recognizing my Pulmonary Arterial Hypertension Patient”, participants will be able to: Define pulmonary hypertension (PH) and its classification; Define pulmonary arterial hypertension (PAH) and the approach to facilitate diagnosis; and Discuss the importance of timely identification of patients with PAH and early referral to specialized centres.

Visit https://www.peervoice.com/MZH860 to view the entire programme with slides. After completing “Biologics in Asthma and Nasal Polyposis: Decision-Making in Practice”, participants will be able to: Define the treatable characteristics in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP); Describe the potential consequences of not achieving treatment goals; Summarise how patients with moderate-severe asthma and/or CRSwNP should be monitored; Identify the patient and disease characteristics that would indicate that a patient may benefit from biologic therapy; Assess the impact of attaining treatment goals on clinical practice.

Visit https://www.peervoice.com/XQJ860 to view the entire programme with slides. After completing “Faire le bon choix dans la gestion de l'asthme : optimiser l'utilisation des CSI/BALA”, participants will be able to: Décrire les dernières lignes directrices sur l’asthme concernant l’utilisation des CSI/BALA et leurs implications pour les pharmaciens; Discuter du rôle du pharmacien dans la prise en charge de l’asthme et des stratégies qu’il peut utiliser (ie, évaluation et éducation sur la technique d’inhalation) pour optimiser les soins aux patients.